One can therefore speculate that the clinical benefit of the early onset of SGLT-2 inhibitors in acute decompensated HF might be seen, at least in part, due to improved left ventricular filling; thus, one might advocate for the early start of modern HF therapy in acute decompensated HF. The gene discussed is SLC5A2; the disease is hydrops fetalis.